drugset / Trial / NCT04463472
Study of COVID-19 DNA Vaccine (AG0301-COVID19)
Phase 1/2
Completed
30 enrolled
AnGes, Inc.
Japan Agency for Medical Research and Development · collab
Non-randomizedSequentialOpen-labelPrevention
Summary
This study will assess the safety and immunogenicity of AG0301-COVID19 in healthy adult volunteers.
Timeline
- Start
- 2020-06-29
- Primary completion
- 2020-09-28
- Completion
- 2021-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AG0301-COVID19 | Vaccine | 1 mg | Intramuscular |
| Subject | AG0301-COVID19 | Vaccine | 2 mg | Intramuscular |